- Home
- PCRX vs MAX Comparison
PCRX vs MAX Comparison
Compare PCRX & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- MAX
- Stock Information
- Founded
- PCRX 2006
- MAX 2014
- Country
- PCRX United States
- MAX United States
- Employees
- PCRX N/A
- MAX N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- MAX Industrial Machinery/Components
- Sector
- PCRX Health Care
- MAX Industrials
- Exchange
- PCRX Nasdaq
- MAX Nasdaq
- Market Cap
- PCRX 1.2B
- MAX 582.4M
- IPO Year
- PCRX 2011
- MAX 2020
- Fundamental
- Price
- PCRX $22.73
- MAX $10.44
- Analyst Decision
- PCRX Buy
- MAX Strong Buy
- Analyst Count
- PCRX 8
- MAX 6
- Target Price
- PCRX $28.38
- MAX $17.92
- AVG Volume (30 Days)
- PCRX 492.0K
- MAX 394.0K
- Earning Date
- PCRX 07-29-2025
- MAX 07-30-2025
- Dividend Yield
- PCRX N/A
- MAX N/A
- EPS Growth
- PCRX N/A
- MAX N/A
- EPS
- PCRX N/A
- MAX 0.28
- Revenue
- PCRX $702,772,000.00
- MAX $1,002,364,000.00
- Revenue This Year
- PCRX $7.92
- MAX $24.09
- Revenue Next Year
- PCRX $11.02
- MAX $11.18
- P/E Ratio
- PCRX N/A
- MAX $37.11
- Revenue Growth
- PCRX 3.08
- MAX 148.62
- 52 Week Low
- PCRX $11.16
- MAX $7.33
- 52 Week High
- PCRX $27.64
- MAX $20.91
- Technical
- Relative Strength Index (RSI)
- PCRX 36.58
- MAX 49.08
- Support Level
- PCRX $22.23
- MAX $10.28
- Resistance Level
- PCRX $23.91
- MAX $11.14
- Average True Range (ATR)
- PCRX 0.82
- MAX 0.34
- MACD
- PCRX -0.01
- MAX -0.06
- Stochastic Oscillator
- PCRX 22.03
- MAX 39.21
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.